Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT05522205
Active, not recruiting Not applicable

Regulated Cannabis Access in Basel

NCT05522205 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Health Department of the Canton of Basel-Stadt
Phase
Not applicable
Started
2023-01-31
Last updated
2026-09-02

Condition(s) studied

Cannabis Use DisorderMental Health DisorderPhysical Illness

Investigational drug(s) / intervention(s)

Regulated cannabis access in pharmacies

Regulated cannabis access in pharmacies: The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.

Study summary

The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample) Exclusion Criteria: * pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment

Primary outcome measure(s)

  • Change in problematic cannabis consumption behaviour — 6 / 12 /18 /24 / 30 months
    Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome

Trial sites (1)

FacilityCityRegionStatus
Canton Basel-Stadt Basel Canton of Basel-City
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05522205 on ClinicalTrials.gov ↗ ← All trials in Switzerland